Merrimack Pharmaceuticals Inc (MACK.OQ)
MACK.OQ on NASDAQ Stock Exchange Global Market
8.33USD
25 Apr 2018
8.33USD
25 Apr 2018
Change (% chg)
$-0.13 (-1.54%)
$-0.13 (-1.54%)
Prev Close
$8.46
$8.46
Open
$8.48
$8.48
Day's High
$8.48
$8.48
Day's Low
$8.22
$8.22
Volume
18,324
18,324
Avg. Vol
44,549
44,549
52-wk High
$39.85
$39.85
52-wk Low
$7.41
$7.41
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- ownership
- filings
- deals
- private equity
- third-party document and information retrieval
- estimates
- fundamentals
- economics
- events
- news
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
| Name | Age | Since | Current Position |
|---|---|---|---|
Gary Crocker |
64 | 2017 | Chairman of the Board |
Richard Peters |
54 | 2017 | President, Chief Executive Officer, Director |
Jean Franchi |
50 | 2017 | Chief Financial Officer,Principal Financial Officer, Principal Accounting Officer, Treasurer |
John Green |
37 | 2017 | Controller |
Ellen Forest |
2017 | Head of Human Resources |
- BRIEF-Merrimack Provides Business Update And Reports 2017 Financial Results
- BRIEF-Merrimack Strengthens SHERLOC Study Of MM-121 In Non-Small Cell Lung Cancer
- BRIEF-Merrimack Says Dosed First Patient In Randomized Phase 2 Clinical Study Of MM-121
- French pharma group Ipsen sees more asset purchases, U.S. growth
- BRIEF-Merrimack Pharmaceuticals Files For Mixed Shelf Of Upto $150 Mln